RLAY
HealthcareRelay Therapeutics, Inc. · Biotechnology · $3B
What is Relay Therapeutics, Inc.?
Relay Therapeutics is a clinical-stage precision medicines company focused on targeted oncology and genetic diseases. It applies computational protein-motion modeling to discover small molecule drug candidates with the potential to address difficult-to-treat cancers.
Relay Therapeutics generates revenue potential through advancing a pipeline of oral small molecule inhibitors targeting specific genetic alterations in cancer. Its platform integrates computational modeling — developed in collaboration with D. E. Shaw Research — with traditional drug discovery to identify compounds that interact with proteins in motion rather than static structures. The company also partners with Genentech for development and commercialization of one of its pipeline assets, providing external validation of its approach.
Incorporated in 2015 and headquartered in Cambridge, Massachusetts, the company operates at the forefront of computationally driven drug discovery.
- RLY-4008 — oral FGFR2 inhibitor for FGFR2-altered solid tumors
- RLY-2608 — mutant-selective PI3Kα inhibitor program
- RLY-1971 — oral SHP2 inhibitor in Phase 1 trials
- Computational protein-motion drug discovery platform
- Genentech collaboration for pipeline co-development
Is RLAY a Good Stock to Buy?
UQS Score rates RLAY as Below Average overall, reflecting the realities of a pre-revenue clinical-stage biotech.
The Growth pillar stands out as the clearest bright spot, consistent with a company advancing multiple clinical programs simultaneously. The Risk pillar also registers as Good, suggesting the balance sheet and operational structure carry relatively manageable near-term risk for a company at this stage.
Both the Quality and Moat pillars score Weak — expected for a clinical-stage company with no commercial products — while the Valuation pillar reads as Elevated, meaning the market has priced in considerable future success.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RLAY pay dividends?
No — Relay Therapeutics, Inc. does not currently pay a dividend.
Relay Therapeutics does not pay a dividend, which is typical for clinical-stage biotechs. All available capital is directed toward advancing the clinical pipeline, funding research collaborations, and sustaining operations through the drug development process. Income-focused investors should look elsewhere; growth-oriented investors understand that reinvestment is the primary value-creation mechanism at this stage.
When does RLAY report earnings?
Relay Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly results center on pipeline progress, cash runway, and operating expenses rather than revenue growth. Investors typically focus on clinical trial updates and collaboration milestones as the key indicators of progress.
For the most recent quarter's results and pipeline updates, visit Relay Therapeutics' investor relations page directly.
RLAY Price History
-47.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Relay Therapeutics, Inc.?
Based on Relay Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RLAY Long-term Outlook
The Growth pillar's Strong rating reflects meaningful near-term catalysts tied to clinical readouts across multiple programs. However, the Elevated Valuation pillar signals that much of this potential is already reflected in the current price, leaving limited margin for setbacks. The Good Risk rating provides some reassurance around financial stability, but the Weak Quality and Moat pillars are reminders that commercial durability remains unproven.
Growth drivers
- Clinical advancement of RLY-4008 in FGFR2-altered solid tumors
- Potential milestone and royalty value from the Genentech collaboration
- Expansion of the computational platform to new oncology targets
Key risks
- Clinical trial failure or delays across any lead program
- Elevated valuation leaves little room for disappointment
- No approved products means the company remains dependent on external funding
RLAY vs Peers
Relay Therapeutics operates in a competitive clinical-stage oncology and precision medicine landscape alongside several similarly positioned biotechs.
Vera focuses on immunology and kidney disease rather than oncology, giving it a distinct therapeutic area profile compared to Relay's cancer-centric pipeline.
IDEAYA pursues synthetic lethality approaches in oncology, competing in the precision oncology space but with a different mechanistic strategy than Relay's protein-motion platform.
Arcutis targets dermatological conditions with its small molecule and biologic pipeline, sharing the clinical-stage biotech profile but operating in an entirely different disease area.
Frequently Asked Questions
What does Relay Therapeutics do?
Relay Therapeutics discovers and develops oral small molecule drugs targeting specific genetic alterations in cancer and genetic diseases. Its platform uses computational modeling of protein motion — developed with D. E. Shaw Research — to identify drug candidates that traditional methods might miss. The company is currently advancing multiple programs through clinical trials.
Does RLAY pay dividends?
No, Relay Therapeutics does not pay a dividend. As a clinical-stage company with no commercial products, it reinvests all capital into research, clinical development, and operations. Dividend income is not part of the RLAY investment thesis at this stage.
When does RLAY report earnings?
Relay Therapeutics follows a standard quarterly reporting schedule for US-listed companies. Because it is pre-revenue, investors focus more on pipeline milestones and cash position than traditional earnings metrics. Check the company's investor relations page for the current reporting calendar.
Is RLAY a good stock to buy?
UQS Score rates RLAY as Below Average overall. The Growth pillar is Strong and the Risk pillar is Good, but Quality and Moat are both Weak — typical for a clinical-stage biotech — and Valuation is Elevated. Whether it fits a portfolio depends on individual risk tolerance and conviction in the pipeline. View the full breakdown on UQS Score.
Is RLAY overvalued?
The UQS Valuation pillar for RLAY is rated Elevated, suggesting the current market price reflects significant future success already. For a pre-revenue clinical-stage company, this means investors are paying a premium for pipeline optionality. The complete valuation metrics are available to Pro members on UQS Score.
How does RLAY compare to its competitors?
Relay Therapeutics competes in the clinical-stage precision medicine space alongside companies like IDEAYA Biosciences and Vera Therapeutics. What differentiates Relay is its computational protein-motion platform and its collaboration structure with both D. E. Shaw Research and Genentech. UQS Score provides side-by-side pillar comparisons for registered users.
What is RLAY's market cap bracket?
Relay Therapeutics is classified as a mid-cap company. This places it above most early-stage micro-cap biotechs in terms of market recognition and liquidity, though it remains pre-revenue and carries the risk profile typical of clinical-stage drug developers.
Who founded Relay Therapeutics?
Relay Therapeutics was incorporated in 2015 under the name Allostery, Inc. before rebranding in December 2015. Founding details and leadership history are publicly available through the company's official filings and investor relations materials.
Is RLAY a long-term quality investment?
As a long-term quality indicator, RLAY's UQS profile is mixed. The Strong Growth pillar points to meaningful pipeline catalysts ahead, but Weak Quality and Moat scores reflect the absence of commercial products and durable competitive advantages. Long-term quality typically improves if clinical programs succeed and the company transitions toward commercialization.
What is the main competitive advantage of Relay Therapeutics?
Relay's core differentiation is its computational drug discovery platform, which models protein motion rather than static protein structures. This approach — developed in partnership with D. E. Shaw Research — is designed to identify drug candidates that conventional methods overlook, particularly in historically difficult oncology targets.
What sector does RLAY belong to?
Relay Therapeutics operates in the Healthcare sector, specifically within clinical-stage precision oncology and genetic medicine. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score to compare quality profiles across the industry.
Is RLAY a growth stock or value stock?
Based on its UQS profile, RLAY leans firmly toward growth. The Growth pillar is rated Strong, reflecting active clinical advancement, while the Valuation pillar is Elevated — a combination more consistent with a growth-oriented investment than a value opportunity.
Unlock Full RLAY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare RLAY side-by-side with clinical-stage peers
- ✓See the complete Quality and Moat breakdown
- ✓Track pipeline-driven Growth signals over time
- ✓Get the full analyst view available to Pro members
Pro Analysis
RLAY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | 34.5 | 0.8 | 19.0 | 95.2 | 69.7 | 0.0 | +5.2 |
| May 8, 2026 | 29.3 | 0.0 | 19.0 | 95.2 | 36.9 | 0.0 | -4.8 |
| May 1, 2026 | 34.1 | 0.8 | 19.0 | 90.4 | 73.6 | 0.0 | 0.0 |
| Apr 26, 2026 | 34.1 | 0.8 | 19.0 | 90.3 | 73.6 | 0.0 | -1.9 |
| Apr 14, 2026 | 36.0 | 0.8 | 19.0 | 99.9 | 73.6 | 0.0 | -7.7 |
| Apr 13, 2026 | 43.7 | 0.8 | 50.0 | 99.9 | 73.6 | 0.0 | +7.7 |
| Apr 2, 2026 | 36.0 | 0.8 | 19.0 | 99.9 | 73.6 | 0.0 | — |
RLAY — Pillar Breakdown
Quality
— 0.8/100 (25%)Relay Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 95.0/100 (20%)Relay Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.7/100 (15%)Relay Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Relay Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)Relay Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RLAY.
Score Composition
Financial Data
More Stock Analysis
How is the RLAY UQS Score Calculated?
The UQS (Unified Quality Score) for Relay Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Relay Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Relay Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.